New insights into molecular mechanisms of sunitinib-associated side effects

• Published in: Molecular cancer therapeutics Vol. 10; no. 12; pp. 2215 - 2223
• Main Authors: Aparicio-Gallego, Guadalupe, Blanco, Moisés, Figueroa, Angélica, García-Campelo, Rosario, Valladares-Ayerbes, Manuel, Grande-Pulido, Enrique, Antón-Aparicio, Luis
• Format: Journal Article
• Language: English
• Published: United States 01.12.2011
• Subjects: Animals; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - genetics; Carcinoma, Renal Cell - pathology; Drug-Related Side Effects and Adverse Reactions - genetics; Humans; Hypertension - chemically induced; Hypertension - genetics; Hypertension - metabolism; Hypothyroidism - chemically induced; Hypothyroidism - genetics; Hypothyroidism - metabolism; Indoles - adverse effects; Indoles - therapeutic use; Kidney Neoplasms - drug therapy; Kidney Neoplasms - genetics; Kidney Neoplasms - pathology; Models, Biological; Pigmentation Disorders - chemically induced; Pigmentation Disorders - genetics; Pigmentation Disorders - metabolism; Pyrroles - adverse effects; Pyrroles - therapeutic use; Signal Transduction - drug effects; Signal Transduction - genetics
• ISSN: 1535-7163; 1538-8514
• DOI: 10.1158/1535-7163.MCT-10-1124

The introduction of targeted therapy represents a major advance in the treatment of tumor progression. Targeted agents are a novel therapeutic approach developed to disrupt different cellular signaling pathways. The tyrosine kinase inhibitor sunitinib specifically blocks multiple tyrosine kinase receptors that are involved in the progression of many tumors. Sunitinib is the current standard of care in first-line treatment of advanced renal cell carcinoma, and it is approved in imatinib-intolerant and imatinib-refractory gastrointestinal stromal tumors. However, it is increasingly evident that sunitinib may display collateral effects on other proteins beyond its main target receptors, eliciting undesirable and unexpected adverse events. A better understanding of the molecular mechanisms underlying these undesirable sunitinib-associated side effects will help physicians to maximize efficacy of sunitinib and minimize adverse events. Here, we focus on new insights into molecular mechanisms that may mediate sunitinib-associated adverse events.